American Journal of Cardiology
Volume 105, Issue 5 , Pages 687-693 , 1 March 2010

The RecordAF Study: Design, Baseline Data, and Profile of Patients According to Chosen Treatment Strategy for Atrial Fibrillation

  • Jean-Yves Le Heuzey, MD

      Affiliations

    • Hôpital Georges Pompidou–APHP, University Paris V, Paris, France
    • Corresponding Author InformationCorresponding author: Tel: +33 (1) 56 09 3701; fax: +33 (1) 56 09 3047
    • ,
  • Günter Breithardt, MD

      Affiliations

    • University of Muenster, Muenster, Germany
    • ,
  • John Camm, MD

      Affiliations

    • St. George's Hospital Medical School, London, United Kingdom
    • ,
  • Harry Crijns, MD

      Affiliations

    • Academisch Ziekenhuis Maastricht, Maastricht, The Netherlands
    • ,
  • Paul Dorian, MD

      Affiliations

    • St. Michaels's Hospital, Toronto, Ontario, Canada
    • ,
  • Peter R. Kowey, MD

      Affiliations

    • Lankenau Hospital, Wynnewood, Pennsylvania
    • ,
  • Ihsen Merioua, MD

      Affiliations

    • sanofi-aventis, Paris, France
    • ,
  • Eric N. Prystowsky, MD

      Affiliations

    • St. Vincent Hospital and Health Center Program, Indianapolis, Indiana
    • ,
  • Peter J. Schwartz, MD

      Affiliations

    • University of Pavia and IRCCS, Fondazione Policlinico San Matteo, Pavia, Italy
    • ,
  • Christian Torp-Pedersen, MD

      Affiliations

    • University of Copenhagen and Gentofte Hospital, Hellerup, Denmark
    • ,
  • William Weintraub, MD

      Affiliations

    • Christiana Center for Outcomes Research, Newark, Delaware

Received 16 July 2009 ,Revised 14 October 2009 ,Accepted 14 October 2009.

References 

  1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA. 2001;285:2370–2375
  2. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J 2006. 2006;27:1979–2030
  3. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Mahe I, Bergmann JF. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med. 2006;166:719–728
  4. Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003;41:1690–1696
  5. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834–1840
  6. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825–1833
  7. Le Heuzey JY, Paziaud O, Piot O, Said MA, Copie X, Lavergne T, et al. Cost of care distribution in atrial fibrillation patients: the COCAF study. Am Heart J. 2004;147:121–126
  8. Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW, et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005;26:2422–2434
  9. McCabe JM, Johnson CJ, Marcus GM. Internal medicine physicians' perceptions regarding rate versus rhythm control for atrial fibrillation. Am J Cardiol. 2009;103:535–539
  10. World Medical Association General Assembly. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Int Bioethique. 2004;15:124–129
  11. International Epidemiological Association (IEA). Good Epidemiological Practice (GEP)-IEA Guidelines for proper conduct of epidemiological research. http://www.ieaweb.orgAccessed 5 November 2009
  12. Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC, et al. Outcome parameters for trials in atrial fibrillation: executive summary. Eur Heart J. 2007;28:2803–2817
  13. The EuroQol Group. EQ-5D: A standardised instrument for use as a measure of health outcome. www.euroqol.org/Accessed 5 November 2009
  14. Dorian P, Paquette M, Newman D, Green M, Connolly SJ, Talajic M, et al. Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation. Am Heart J. 2002;143:984–990
  15. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA. 2001;2370–2375
  16. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114:119–125
  17. Lévy S, Maarek M, Coumel P, Guize L, Lekieffre J, Medvedowsky JL, et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. Circulation. 1999;99:3028–3035
  18. Meiltz A, Zimmermann M, Urban P, Bloch A. Atrial fibrillation management by practice cardiologists: a prospective survey on the adherence to guidelines in the real world. Europace. 2008;10:674–680
  19. Nabauer M, Gerth A, Limbourg T, Schneider S, Oeff M, Kirchhof P, et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace. 2009;11:423–434
  20. Kerr C, Boone J, Connolly S, Greene M, Klein G, Sheldon R, et al. Follow-up of atrial fibrillation: the initial experience of the Canadian Registry of Atrial Fibrillation. Eur Heart J. 1996;17(Suppl C):48–51
  21. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet. 2000;356:1789–1794

 The registry was funded by sanofi-aventis, Paris, France; and editorial support was funded by sanofi-aventis.

PII: S0002-9149(09)02487-4

doi: 10.1016/j.amjcard.2009.10.012

American Journal of Cardiology
Volume 105, Issue 5 , Pages 687-693 , 1 March 2010

Article Tools

* Image Usage & Resolution